CoChat

Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage

Open access

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

Abstract

Classical dendritic cells (cDCs), monocytes, and plasmacytoid DCs (pDCs) arise from a common bone marrow precursor (macrophage and DC progenitors [MDPs]) and express many of the same surface markers, including CD11c. We describe a previously uncharacterized zinc finger transcription factor, zDC (Zbtb46, Btbd4), which is specifically expressed by cDCs and committed cDC precursors but not by monocytes, pDCs, or other immune cell populations. We inserted diphtheria toxin (DT) receptor (DTR) cDNA into the 3' UTR of the zDC locus to serve as an indicator of zDC expression and as a means to specifically deplete cDCs. Mice bearing this knockin express DTR in cDCs but not other immune cell populations, and DT injection into zDC-DTR bone marrow chimeras results in cDC depletion. In contrast to previously characterized CD11c-DTR mice, non-cDCs, including pDCs, monocytes, macrophages, and NK cells, were spared after DT injection in zDC-DTR mice. We compared immune responses to Toxoplasma gondii and MO4 melanoma in DT-treated zDC- and CD11c-DTR mice and found that immunity was only partially impaired in zDC-DTR mice. Our results indicate that CD11c-expressing non-cDCs make significant contributions to initiating immunity to parasites and tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20112675

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. zDC expression is specific to cDCs. (A) Analysis of gene array data of mouse DEC-205+ (CD8+) cDCs, DCIR2+ (CD4+) cDCs, pre-DCs, CDPs, MDPs, and monocytes. (B) Heat maps showing normalized zDC expression depicted on log2 scale from three zDC probes on Affymetrix 430 2.0 chips. All populations were prepared in triplicate. (C) zDC transcript levels in mouse MPs, MDPs, CDPs, pre-DCs, splenic and lung cDC subsets, pDCs, and steady-state and activated monocytes determined by Q-PCR and normalized to GAPDH. All populations were prepared in triplicate and error bars indicate SEM. (D) zDC Western blot of mouse CD11b-enriched monocytes/macrophages, PDCA-1–enriched pDCs, and sorted DEC-205+ and DCIR2+ cDCs. Histone H4 blot is shown as a loading control. The blot represents one experiment of three with equivalent results. Diluted cDC lysates (10 µg) are included to show that zDC protein is still detectable even with limited cell lysate input. (E) Gene array expression of human ZDC (probe 227329_at on Affymetrix U133 Plus 2.0) by sorted human blood populations. Error bars indicate SEM. This panel was adapted with permission from Robbins et al. (2008). (F) Dendrogram of vertebrate zDC amino acid sequences (left) and percent identity to mouse (right).
Figure 1. zDC expression is specific to cDCs. (A) Analysis of gene array data of mouse DEC-205+ (CD8+) cDCs, DCIR2+ (CD4+) cDCs, pre-DCs, CDPs, MDPs, and monocytes. (B) Heat maps showing normalized zDC expression depicted on log2 scale from three zDC probes on Affymetrix 430 2.0 chips. All populations were prepared in triplicate. (C) zDC transcript levels in mouse MPs, MDPs, CDPs, pre-DCs, splenic and lung cDC subsets, pDCs, and steady-state and activated monocytes determined by Q-PCR and normalized to GAPDH. All populations were prepared in triplicate and error bars indicate SEM. (D) zDC Western blot of mouse CD11b-enriched monocytes/macrophages, PDCA-1–enriched pDCs, and sorted DEC-205+ and DCIR2+ cDCs. Histone H4 blot is shown as a loading control. The blot represents one experiment of three with equivalent results. Diluted cDC lysates (10 µg) are included to show that zDC protein is still detectable even with limited cell lysate input. (E) Gene array expression of human ZDC (probe 227329_at on Affymetrix U133 Plus 2.0) by sorted human blood populations. Error bars indicate SEM. This panel was adapted with permission from Robbins et al. (2008). (F) Dendrogram of vertebrate zDC amino acid sequences (left) and percent identity to mouse (right).CC BY-NC-SA · PubMed Central
Figure 2. DTR expression regulated by the zDC locus permits DT ablation of cDCs. (A) Schematic diagram of wild-type and DTR knockin zDC loci. 5′ and 3′ UTR are shown in black, coding sequences in white, and the locations of BTB/POZ and zinc finger domains are indicated. IRES (gray) and DTR-mCherry (red) are inserted immediately after the endogenous zDC stop codon in exon 5. (B) Western blots for zDC, hDTR, and Histone H4 (loading control) on CD11c-enriched splenocytes from zDC+/+, zDC+/DTR, and zDCDTR/DTR mice. (C) Flow cytometry histograms of DTR staining by CD8+ and CD4+ cDCs (Lin−Ly6C−CD11chiMHCII+), pDCs (Lin−CD11cintPDCA-1+), monocytes (Lin−CD11b+CD115+), B cells (CD3−NK1.1−CD19+), and T cells (CD3+CD19−NK1.1−) from the spleens (spl), skLN, and mLN of zDC-DTR mice (black line) and wild-type littermates (gray shaded). (D) Flow cytometry plots of splenic cDCs (gated on Lin−) and bone marrow pre-DCs (gated on Lin−CD45R−CD11c+MHCII−) in zDC-DTR bone marrow chimeras injected with PBS or DT. Numbers indicate percentage of organ. Graphs on right represent three to four experiments with each point representing one mouse and horizontal lines representing the means. (E) CD11chiMHCII+ cDC and CD11c+MHCIIhi mDC abundance in skLN, mLN, lung, and liver in PBS- and DT-treated zDC-DTR bone marrow chimeras, gated on Lin− in skLN and mLN, and Lin−CD45+ in liver and lung. (F) Flt3L concentrations in sera of DT-treated zDC-DTR bone marrow chimeras determined by ELISA at multiple time points after DT injection. (G and H) cDC abundance in spleen (G) and skLN (H) at multiple time points after DT injection. Results represent two to three experiments with two to three mice per group per experiment. Error bars indicate SEM. Lin−; CD3−CD19−NK1.1−.
Figure 2. DTR expression regulated by the zDC locus permits DT ablation of cDCs. (A) Schematic diagram of wild-type and DTR knockin zDC loci. 5′ and 3′ UTR are shown in black, coding sequences in white, and the locations of BTB/POZ and zinc finger domains are indicated. IRES (gray) and DTR-mCherry (red) are inserted immediately after the endogenous zDC stop codon in exon 5. (B) Western blots for zDC, hDTR, and Histone H4 (loading control) on CD11c-enriched splenocytes from zDC+/+, zDC+/DTR, and zDCDTR/DTR mice. (C) Flow cytometry histograms of DTR staining by CD8+ and CD4+ cDCs (Lin−Ly6C−CD11chiMHCII+), pDCs (Lin−CD11cintPDCA-1+), monocytes (Lin−CD11b+CD115+), B cells (CD3−NK1.1−CD19+), and T cells (CD3+CD19−NK1.1−) from the spleens (spl), skLN, and mLN of zDC-DTR mice (black line) and wild-type littermates (gray shaded). (D) Flow cytometry plots of splenic cDCs (gated on Lin−) and bone marrow pre-DCs (gated on Lin−CD45R−CD11c+MHCII−) in zDC-DTR bone marrow chimeras injected with PBS or DT. Numbers indicate percentage of organ. Graphs on right represent three to four experiments with each point representing one mouse and horizontal lines representing the means. (E) CD11chiMHCII+ cDC and CD11c+MHCIIhi mDC abundance in skLN, mLN, lung, and liver in PBS- and DT-treated zDC-DTR bone marrow chimeras, gated on Lin− in skLN and mLN, and Lin−CD45+ in liver and lung. (F) Flt3L concentrations in sera of DT-treated zDC-DTR bone marrow chimeras determined by ELISA at multiple time points after DT injection. (G and H) cDC abundance in spleen (G) and skLN (H) at multiple time points after DT injection. Results represent two to three experiments with two to three mice per group per experiment. Error bars indicate SEM. Lin−; CD3−CD19−NK1.1−.CC BY-NC-SA · PubMed Central
Figure 3. DT ablation in zDC-DTR bone marrow chimeras is specific to cDCs and spares other CD11c-expressing cells. (A–I) Steady-state splenic cDCs (A) and bone marrow pre-DCs (B; as defined in Fig. 2 D), CD45+CD3–B220–CD11chiMHCII+ small intestine (SI) lamina propria DCs (C, top) and DC subsets (C, bottom), CD19+ splenic B cells (D), CD19−NK1.1−CD3+ T cells (E), Lin−CD11b+Ly6G+ neutrophils (F), CD3−CD19−NK1.1+ NK cells (G), Lin−CD11cintPDCA-1+ pDCs (H), and Lin−Flt3−CD11b+Ly6G−CD115+ monocytes (I) in PBS- or DT-treated steady-state zDC-DTR bone marrow chimeras. Results represent three to four experiments. (J) Lin−CD11b+Ly6G−CD11c+Ly6C+ activated monocytes in PBS- or DT-treated L. monocytogenes–infected zDC-DTR bone marrow chimeras. Graphs on the right show percentage of indicated population in DT-treated WT, zDC-DTR, and CD11c-DTR bone marrow chimeras with each point representing one mouse and horizontal lines showing the mean per group.
Figure 3. DT ablation in zDC-DTR bone marrow chimeras is specific to cDCs and spares other CD11c-expressing cells. (A–I) Steady-state splenic cDCs (A) and bone marrow pre-DCs (B; as defined in Fig. 2 D), CD45+CD3–B220–CD11chiMHCII+ small intestine (SI) lamina propria DCs (C, top) and DC subsets (C, bottom), CD19+ splenic B cells (D), CD19−NK1.1−CD3+ T cells (E), Lin−CD11b+Ly6G+ neutrophils (F), CD3−CD19−NK1.1+ NK cells (G), Lin−CD11cintPDCA-1+ pDCs (H), and Lin−Flt3−CD11b+Ly6G−CD115+ monocytes (I) in PBS- or DT-treated steady-state zDC-DTR bone marrow chimeras. Results represent three to four experiments. (J) Lin−CD11b+Ly6G−CD11c+Ly6C+ activated monocytes in PBS- or DT-treated L. monocytogenes–infected zDC-DTR bone marrow chimeras. Graphs on the right show percentage of indicated population in DT-treated WT, zDC-DTR, and CD11c-DTR bone marrow chimeras with each point representing one mouse and horizontal lines showing the mean per group.CC BY-NC-SA · PubMed Central
Figure 4. CD11c+CD14+ cells in skLNs derive from cDCs. (A and B) CD11c+MHCII+CD14+ cells in skLN (A) and Lin−Flt3−CD11b+Ly6G−CD115+ monocytes (B) in blood 24 h after PBS or LPS injection in WT and Flt3L−/− mice. Graphs on the right summarize three experiments, with each point representing one mouse and the horizontal bars showing the mean. (C) CD11c+MHCII+CD14+ cells in skLN 24 h after LPS injection in PBS- or DT-treated zDC-DTR bone marrow chimeras. (D) CD45.1+ WT versus CD45.2+ zDC-DTR contribution to CD11c+MHCII+CD14+ cells in skLN 24 h after LPS treatment in PBS- or DT-treated WT:zDC-DTR mixed bone marrow chimeras. Error bars indicate SEM.
Figure 4. CD11c+CD14+ cells in skLNs derive from cDCs. (A and B) CD11c+MHCII+CD14+ cells in skLN (A) and Lin−Flt3−CD11b+Ly6G−CD115+ monocytes (B) in blood 24 h after PBS or LPS injection in WT and Flt3L−/− mice. Graphs on the right summarize three experiments, with each point representing one mouse and the horizontal bars showing the mean. (C) CD11c+MHCII+CD14+ cells in skLN 24 h after LPS injection in PBS- or DT-treated zDC-DTR bone marrow chimeras. (D) CD45.1+ WT versus CD45.2+ zDC-DTR contribution to CD11c+MHCII+CD14+ cells in skLN 24 h after LPS treatment in PBS- or DT-treated WT:zDC-DTR mixed bone marrow chimeras. Error bars indicate SEM.CC BY-NC-SA · PubMed Central
Figure 5. Macrophage populations in the spleen and skLNs are intact after DT injection in zDC-DTR mice. (A) Splenic Lin−CD11cintCD11bloF4/80+ red pulp macrophages measured by flow cytometry in PBS- or DT-treated zDC-DTR bone marrow chimeras. Results are representative of three independent experiments with each point on the graph representing one mouse and the horizontal bars representing the means. (B–E) Spleen and skLNs from DT-treated WT, zDC-DTR, and CD11c-DTR mice were stained with B220 (green) to visualize B cell zones and appropriate macrophage markers (red). Bars, 100 µm. In the spleen, F4/80 identifies red pulp macrophages (B) and CD169+ marginal zone macrophages (C) which outline B cell zones. (D) F4/80+ medullar macrophages in the skLN. Diagram of LN included with merged image to represent region of LN imaged (dashed box) relative to entire LN (solid outline). (E) CD169+ subcapsular sinus macrophages located on the outer border of LN sections. Images represent results from three independent sets of experiments.
Figure 5. Macrophage populations in the spleen and skLNs are intact after DT injection in zDC-DTR mice. (A) Splenic Lin−CD11cintCD11bloF4/80+ red pulp macrophages measured by flow cytometry in PBS- or DT-treated zDC-DTR bone marrow chimeras. Results are representative of three independent experiments with each point on the graph representing one mouse and the horizontal bars representing the means. (B–E) Spleen and skLNs from DT-treated WT, zDC-DTR, and CD11c-DTR mice were stained with B220 (green) to visualize B cell zones and appropriate macrophage markers (red). Bars, 100 µm. In the spleen, F4/80 identifies red pulp macrophages (B) and CD169+ marginal zone macrophages (C) which outline B cell zones. (D) F4/80+ medullar macrophages in the skLN. Diagram of LN included with merged image to represent region of LN imaged (dashed box) relative to entire LN (solid outline). (E) CD169+ subcapsular sinus macrophages located on the outer border of LN sections. Images represent results from three independent sets of experiments.CC BY-NC-SA · PubMed Central
Figure 6. Comparison of DT treatment in zDC- and CD11c-DTR bone marrow chimeras during immune responses. (A) CFSE-labeled CD45.1+ OT-I and OT-II cells were transferred into CD45.2+ recipients, treated with DT 24 h later, and injected with 20 µg OVA i.v. another 24 h later. CFSE dilution of CD45.1+ OT-I and OT-II cells was measured by flow cytometry 3 d after OVA injection. These experiments were repeated twice with two to three mice per group per experiment. The horizontal bar shows the mean per group. (B) 500,000 bulk splenocytes from DT-treated CD45.2+ C57BL/6 bone marrow chimeras were co-cultured with 50,000 CFSE-labeled CD45.1+ BALB/c T cells. CFSE dilution of CD45.1+ BALB/c T cells was measured by flow cytometry after 5 d. Results represent three experiments with two mice per group per experiment. The horizontal bar shows the mean per group. (C and D) PBS- and DT-treated zDC-DTR bone marrow chimeras were immunized with poly I:C plus α-CD40 and α-DEC-205-GAGp24 or α-Treml4-GAGp24, and IFN-γ and IL-2 production by splenic CD3+CD4+ T cells was measured after restimulation in vitro with p24 or p17 control peptide. This was repeated twice with four to five mice per group per experiment. Error bars indicate SEM. (E–G) Mice were treated with DT before infection with 15 T. gondii cysts by gavage and DT ablation was maintained until 8 d after infection when mice were euthanized. (E) The abundance of Lin−CD11chi cDCs in the spleens from DT-treated T. gondii–infected WT, zDC-DTR, and CD11c-DTR bone marrow chimeras determined by flow cytometry. (F) The percentage of CD3+CD4+ T cells producing IFN-γ in the mLN quantified by intracellular cytokine staining after restimulation in vitro. Uninfected mice were included as naive controls. Statistical significance was determined using a Student’s t test. Results were pooled from three experiments with two to three mice per group per experiment. The horizontal bar shows the mean of each group. (G) Q-PCR of whole lung cDNA for T. gondii tachyzoite-specific SAG2 expression normalized to GAPDH. Uninfected mice were included as naive controls. ND indicates not detected. Error bars indicate SEM. Statistical significance was determined by Student’s t test: *, P < 0.01; **, P < 0.005. (H and I) Mice were injected with DT before i.v. immunization with Ad-OVA plus poly I:C and α-CD40, and DT ablation was maintained for 15 d. 1 mo after immunization, mice were challenged with 105 MO4 cells i.v. and followed for survival. Each group contained 5–10 mice per group per experiment and was repeated three times. (J) As in H, but immunization was with 20 × 106 irradiated MO4 melanoma cells (7,500 rad) plus poly I:C and α-CD40, and challenge was with 105 MO4 cells s.c. 1 mo later. The experiment was repeated twice with five mice per group per experiment.
Figure 6. Comparison of DT treatment in zDC- and CD11c-DTR bone marrow chimeras during immune responses. (A) CFSE-labeled CD45.1+ OT-I and OT-II cells were transferred into CD45.2+ recipients, treated with DT 24 h later, and injected with 20 µg OVA i.v. another 24 h later. CFSE dilution of CD45.1+ OT-I and OT-II cells was measured by flow cytometry 3 d after OVA injection. These experiments were repeated twice with two to three mice per group per experiment. The horizontal bar shows the mean per group. (B) 500,000 bulk splenocytes from DT-treated CD45.2+ C57BL/6 bone marrow chimeras were co-cultured with 50,000 CFSE-labeled CD45.1+ BALB/c T cells. CFSE dilution of CD45.1+ BALB/c T cells was measured by flow cytometry after 5 d. Results represent three experiments with two mice per group per experiment. The horizontal bar shows the mean per group. (C and D) PBS- and DT-treated zDC-DTR bone marrow chimeras were immunized with poly I:C plus α-CD40 and α-DEC-205-GAGp24 or α-Treml4-GAGp24, and IFN-γ and IL-2 production by splenic CD3+CD4+ T cells was measured after restimulation in vitro with p24 or p17 control peptide. This was repeated twice with four to five mice per group per experiment. Error bars indicate SEM. (E–G) Mice were treated with DT before infection with 15 T. gondii cysts by gavage and DT ablation was maintained until 8 d after infection when mice were euthanized. (E) The abundance of Lin−CD11chi cDCs in the spleens from DT-treated T. gondii–infected WT, zDC-DTR, and CD11c-DTR bone marrow chimeras determined by flow cytometry. (F) The percentage of CD3+CD4+ T cells producing IFN-γ in the mLN quantified by intracellular cytokine staining after restimulation in vitro. Uninfected mice were included as naive controls. Statistical significance was determined using a Student’s t test. Results were pooled from three experiments with two to three mice per group per experiment. The horizontal bar shows the mean of each group. (G) Q-PCR of whole lung cDNA for T. gondii tachyzoite-specific SAG2 expression normalized to GAPDH. Uninfected mice were included as naive controls. ND indicates not detected. Error bars indicate SEM. Statistical significance was determined by Student’s t test: *, P < 0.01; **, P < 0.005. (H and I) Mice were injected with DT before i.v. immunization with Ad-OVA plus poly I:C and α-CD40, and DT ablation was maintained for 15 d. 1 mo after immunization, mice were challenged with 105 MO4 cells i.v. and followed for survival. Each group contained 5–10 mice per group per experiment and was repeated three times. (J) As in H, but immunization was with 20 × 106 irradiated MO4 melanoma cells (7,500 rad) plus poly I:C and α-CD40, and challenge was with 105 MO4 cells s.c. 1 mo later. The experiment was repeated twice with five mice per group per experiment.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 70 references

Cited by

Items 101–200 of 524

Metadata

Authors
Meredith, M. M., Liu, K., Darrasse-Jeze, G., Kamphorst, A. O., Schreiber, H. A., Guermonprez, P., Idoyaga, J., Cheong, C., Yao, K.-H., Niec, R. E., & Nussenzweig, M. C.
Affiliations
  • Howard Hughes Medical Institute (US)
  • Columbia University (US)
  • Department of Biotherapy, Institut National de la Santé et de la Recherche Médicale, Faculteì de meìdecine, Universiteì Paris Descartes, Sorbonne Paris Citeì, Paris F-75015, France 5
  • Memorial Sloan Kettering Cancer Center (US)
Corresponding author
Nussenzweig, Michel C.
Venue
Journal of Experimental Medicine
Published
2012-05-21
Volume
209
Issue
6
Pages
1153-1165
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2141214625
Cited by
524
References
70
Citations by year
2026: 17 · 2025: 32 · 2024: 19 · 2023: 24 · 2022: 33 · 2021: 41 · 2020: 30 · 2019: 41 · 2018: 31 · 2017: 41 · 2016: 53 · 2015: 42 · 2014: 42 · 2013: 58 · 2012: 20
FWCI
22.66
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (submittedVersion)
Funders
  • Howard Hughes Medical Institute
  • National Institute of General Medical Sciences (T32GM007739)
  • National Institute of Allergy and Infectious Diseases (AI 051573, P01AI051573)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30AR044535)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
Keywords
myeloid dendritic cells, Zbtb46, zinc finger transcription factor, dendritic cell lineage, dendritic cell depletion, diphtheria toxin receptor, CD11c, plasmacytoid dendritic cells, monocytes, Toxoplasma gondii, melanoma, antitumor immunity, parasite immunity, bone marrow chimeras
MeSH terms
Animals, Dendritic Cells, Diphtheria Toxin, Gene Expression Regulation, Killer Cells, Natural, Macrophages, Melanoma, Mice, Inbred C57BL, Monocytes, Toxoplasma, Toxoplasmosis, Transcription Factors, Zinc Fingers, Mice, Knockout, Cell Lineage, 3' Untranslated Regions, Intercellular Signaling Peptides and Proteins, CD11c Antigen, Mice, Heparin-binding EGF-like Growth Factor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.